Electronic ISSN 2287-0237
Heymann MA. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease. Am Heart J 1981;101(6):837–43.
Cucerea M, Simon M, Moldovan E, et al. Congenital Heart Disease Requiring Maintenance of Ductus Arteriosus in Critically Ill Newborns Admitted at A Tertiary Neonatal In- tensive Care Unit. J Crit Care Med. 2016;2(4):185-91.
Akkinapally S, Hundalani SG, Kulkarni M, et al. Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions. Cochrane Neonatal Group, editor. Cochrane Database Syst Rev [Internet]. 2018 Feb 27 [Accessed at July 3, 2019, at http://doi.wiley. com/10.1002/14651858.CD011417.pub2
Tálosi G, Katona M, Túri S. Side-effects of long-term prostaglandin E 1 treatment in neonates. Pediatr Int 2007;49(3):335-40.
Lewis AB, Freed MD, Heymann MA, et al. Side effects of therapy with prostaglandin E1 in infants with critical
congenital heart disease. Circulation 1981;64(5):893-8.
Alhussin W, Verklan MT. Complications of Long-Term Prostaglandin E1 Use in Newborns With Ductal-Dependent Critical Congenital Heart Disease: J Perinat Neonatal Nurs
2016;30(1):73-9.
Carter EL, Garzon MC. Neonatal urticaria due to prostaglandin E1. Pediatr Dermatol 2000;17(1):58-61.
Young GJ, Harter N, Luu M. An unusual migratory polycyclic eruption after administration of prostaglandin E in a neonate. JAAD Case Rep 2016;2(5):377-9.
Wheless L, Murray LE, Siddiqui F, et al. Re: An unusual migratory polycyclic eruption after administration of prostaglandin E in a neonate. JAAD Case Rep 2017;3(4):342-3.
Rao J, Campbell ME, Krol A. The Harlequin Color Change and Association with Prostaglandin E1. Pediatr Dermatol 2004;21(5):573–6.
Sharata H, Postellon DC, Hashimoto K. Subcutaneous fat necrosis, hypercalcemia, and prostaglandin E. Pediatr Dermatol 1995;12(1):43-7.
Eichenfield LF, editor. Textbook of neonatal dermatology. Philadelphia: Saunders; 2001:528.
Greaves MW, Yamamoto S, Mahzoon B. The mast cell: interrelationships between histamine and prostaglandins. Clin Exp Dermatol 1976;1(4):327–9.
Sondergaard J, Greaves MW. Prostaglandin e1: effect on human cutaneous vasculature and skin histamine. Br J Dermatol 1971;84(5):424–8.
Stone DM, Frattarelli DAC, Karthikeyan S, et al. Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease. Pediatr Cardiol 2006;27(3):360–3.
